Virological and Clinical Outcomes of Influenza Outpatients Treated With Baloxavir, Oseltamivir, or Laninamivir in the 2023–2024 Season
Influenza and Other Respiratory Viruses · 2024
DOI: 10.1111/irv.70042 ↗Kurz gefasst
Beobachtungsstudie in der Zeitschrift Influenza and Other Respiratory Viruses, 2024. Verfasst von Takeyuki Goto und 8 weiteren Autor:innen. Beteiligte Einrichtung: Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences (The First Department of Internal Medicine), Fukuoka, Japan. Hauptthemen laut MEDLINE: Influenza, Human, Dibenzothiepins, Antiviral Agents, Oseltamivir. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 20 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Clinical data on patients infected with influenza B Victoria (BV) after the approval of baloxavir is lacking.
Methods
This observational study of the Japanese 2023–2024 influenza season analyzed data from 25 outpatients with A(H1N1)pdm09, 36 with A(H3N2), and 65 with BV. Viral samples were collected before and after administering an antiviral (70 patients received baloxavir and 56 received a neuraminidase inhibitor), on days 1, 5, and 10. Isolated viruses after culturing were amplified using RT‐PCR and sequenced to detect mutations of concern, including acidic protein (PA)‐amino acid (AA) E23X/I38X for influenza A and M34X/I38X for BV. Fever and symptoms were tracked via self‐reporting diaries.
Results
No PA‐AA‐substituted virus was detected from 126 pre‐treatment samples. In the baloxavir cohort, one (7.1%, 1/14) PA I38F‐substituted A(H1N1)pdm09 and two (11.1%, 2/18) PA I38T‐substituted A(H3N2) viruses were isolated on day 5 but not on day 10. No (0%, 0/37) PA‐AA‐substituted BV was detected on day 5 or after. The virus isolation rate on day 5 was higher among patients with BV than with influenza A in both baloxavir (35.1% vs. 14.3% for A(H1N1)pdm09 and 16.7% for A(H3N2)) and oseltamivir‐treated patients (44.4% vs. 0% for A(H1N1)pdm09 and 33.3% for A(H3N2)). Patients with PA‐AA‐substituted influenza A after baloxavir administration did not have longer fever duration than those without virus isolation or with wild‐type virus on day 5, for both A(H1N1)pdm09 and A(H3N2).
Conclusions
Baloxavir‐resistant variants were not detected in influenza BV before treatment, as with A. The emergence of PA‐AA‐substituted influenza A after baloxavir administration was temporal and did not cause prolonged symptoms. No baloxavir‐resistant BV variants were observed after baloxavir administration.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Medicine and Biosystemic Science, Kyushu University Graduate School of Medical Sciences (The First Department of Internal Medicine), Fukuoka, Japan.
- Japan Physicians Association, Tokyo, Japan.
- Kawai Clinic, Gifu, Japan.
- Bando Clinic, Ishikawa, Japan.
- Takasaki Pediatrics and Child Health Clinic, Fukuoka, Japan.
- Shindo Children's Clinic, Fukuoka, Japan.
ORCID-Profile: Takeyuki Goto
Zitieren
APA
Goto, T., Kawai, N., Bando, T., Takasaki, Y., Shindo, S., Sato, T., Tani, N., Chong, Y., & Ikematsu, H. (2024). Virological and Clinical Outcomes of Influenza Outpatients Treated With Baloxavir, Oseltamivir, or Laninamivir in the 2023–2024 Season. Influenza and Other Respiratory Viruses. https://doi.org/10.1111/irv.70042
Vancouver
Goto T, Kawai N, Bando T, Takasaki Y, Shindo S, Sato T, et al. Virological and Clinical Outcomes of Influenza Outpatients Treated With Baloxavir, Oseltamivir, or Laninamivir in the 2023–2024 Season. Influenza and Other Respiratory Viruses. 2024. doi:10.1111/irv.70042
BibTeX
@article{Goto2024,
author = {Goto, Takeyuki and Kawai, Naoki and Bando, Takuma and Takasaki, Yoshio and Shindo, Shizuo and Sato, Tomonori and Tani, Naoki and Chong, Yong and Ikematsu, Hideyuki},
title = {Virological and Clinical Outcomes of Influenza Outpatients Treated With Baloxavir, Oseltamivir, or Laninamivir in the 2023–2024 Season},
journal = {Influenza and Other Respiratory Viruses},
year = {2024},
doi = {10.1111/irv.70042}
}
EUVIMED